GlassScriptPhysician profile
Sunitha Kalyanam
NPI 1639388903
$3,513.55
in general payments reported to CMS, 2019-2025
24 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.34 · 2020: $84.83 · 2021: $427 · 2022: $528 · 2023: $585 · 2024: $1,016 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.22 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $319.16 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $301.33 | 2022-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $300.96 | 2020-2025 | Veltassa |
| Horizon Therapeutics Plc | $248.01 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $210.14 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $208.19 | 2021-2024 | Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $193.92 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.09 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $169.05 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $160.00 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $144.61 | 2021-2025 | Acthar, Terlivaz |
| Daiichi Sankyo INC. | $122.77 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $89.19 | 2019-2021 | |
| Lilly USA, LLC | $78.52 | 2023-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $76.04 | 2023-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $46.96 | 2022-2024 | Benlysta |
| Apellis Pharmaceuticals, INC. | $40.61 | 2025 | Empaveli |
| Ardelyx, INC. | $38.38 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $27.59 | 2021-2023 | Ultomiris |
| Abbvie INC. | $23.69 | 2020 | |
| Kyowa Kirin, INC. | $18.82 | 2025 | |
| Akebia Therapeutics INC | $15.62 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.68 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Kalyanam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.